Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3034701 in healthy volunteers and obesity/overweight
NCT06352437Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2024
- Primary completion
- Oct 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 3034701 in obesity (14 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-Emergent Adverse Events at 130 days. Started Jun 2024; status: completed.
02
Drugs
BI 3034701
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06352437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352437.